Form 4: Humana CEO's Routine Stock Vesting and Tax Sale
Insider Transaction Report
Humana's President & CEO, James A. Rechtin, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities.
Summary
- James A. Rechtin, President & CEO of Humana Inc., reported transactions on January 8, 2026.
- 2,183 shares of Humana Common Stock were acquired through the vesting of Restricted Stock Units (RSUs) at a price of $0.
- Concurrently, 980 shares of Humana Common Stock were disposed of at a price of $279.1475 per share to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, Mr. Rechtin beneficially owns 28,305 shares of Humana Common Stock indirectly through revocable trusts.
- The beneficial ownership of 28,305 shares includes 14,054 restricted stock units, representing a contingent right to receive one share of Humana Inc. common stock.
- Mr. Rechtin also holds 29,230 stock options with an exercise price of $458.185, expiring on January 8, 2031, vesting in annual increments from January 8, 2025, to January 8, 2027.
- Additionally, he holds 15,772 stock options with an exercise price of $367.21, expiring on February 21, 2031, vesting in annual increments from February 21, 2025, to February 21, 2027.
- The RSUs that vested on January 8, 2026, were part of an award granted on January 8, 2024, vesting 33% annually on January 8, 2025, 2026, and 2027.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While shares were sold, it was for tax purposes related to compensation, which is a routine event. The executive continues to hold significant equity, aligning interests with shareholders.
Positives
- The vesting of Restricted Stock Units (RSUs) indicates the executive's continued participation in the company's long-term incentive plans.
- The executive maintains significant beneficial ownership in Humana Inc. common stock and derivative securities, aligning interests with shareholders.
Negatives
- A portion of the vested shares (980 shares) was sold to cover tax liabilities, which is a reduction in direct shareholding, although a common practice.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding Humana Inc.'s business operations or financial performance. It solely reports insider transactions related to executive compensation.
Industry Context
This filing is a routine disclosure of an executive's equity compensation transactions and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard practices for executive incentive plans within publicly traded companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reference to Existing Plan | All equity transactions (RSU vesting and stock option grants) are conducted pursuant to the Company's 2019 Amended & Restated Stock Incentive Plan, indicating adherence to established corporate governance frameworks for executive compensation. | NA | Confirms that executive equity compensation is managed under a pre-existing, approved incentive plan, reflecting standard corporate governance practices. |
Related Party Transactions
- All shares beneficially owned are held indirectly in two revocable trusts for the benefit of the reporting person and their spouse, with both serving as sole trustees. This is a common arrangement for executive shareholdings.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine compensation event. The executive's continued significant equity holdings align interests.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Next Steps
- Future vesting increments for stock options granted on January 8, 2024, and February 21, 2024, are scheduled for January 8, 2027, and February 21, 2027, respectively.
Key Dates
| Date | Description |
|---|---|
| 01/08/2024 | Grant date for a tranche of Incentive and Non-Qualified stock options and Restricted Stock Units (RSUs). |
| 02/21/2024 | Grant date for a tranche of Incentive and Non-Qualified stock options. |
| 01/08/2025 | First annual vesting increment for stock options granted on 01/08/2024 and RSUs granted on 01/08/2024. |
| 02/21/2025 | First annual vesting increment for stock options granted on 02/21/2024. |
| 01/08/2026 | Date of reported transactions, including the vesting of 2,183 Restricted Stock Units and the disposition of 980 shares for tax liability. Also, the second annual vesting increment for stock options granted on 01/08/2024 and RSUs granted on 01/08/2024. |
| 01/12/2026 | Signature date of the reporting person for the filing. |
| 01/08/2027 | Third and final annual vesting increment for stock options granted on 01/08/2024 and RSUs granted on 01/08/2024. |
| 02/21/2027 | Third and final annual vesting increment for stock options granted on 02/21/2024. |
| 01/08/2031 | Expiration date for stock options with an exercise price of $458.185. |
| 02/21/2031 | Expiration date for stock options with an exercise price of $367.21. |
Recommendation
holdThis Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related share sales). It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The executive maintains substantial equity holdings, which is generally a positive for shareholder alignment. Therefore, a 'hold' recommendation is appropriate based solely on this filing, awaiting more comprehensive financial or strategic updates.
Keywords
Humana Inc., HUM, James A. Rechtin, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Share Ownership, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.